Additional Development Activities. Subject to Section 2.12, each Party shall be permitted (i) to undertake Development activities (including Clinical Trials) not contemplated by the Development Plan (for example, a Clinical Trial for an Indication not included in such plans) or (ii) to repeat any Clinical Trial previously conducted under the Development Plan that failed to meet its primary endpoints (collectively, “Additional Development Activities”); provided that such Party complies with the provisions of this Section 3.3.
Appears in 2 contracts
Sources: Collaboration and License Agreement (Agios Pharmaceuticals Inc), Collaboration and License Agreement (Agios Pharmaceuticals Inc)